This site is intended for Healthcare professionals only.

Lupin launches Clobetasol Propionate ointment in US

Lupin launches Clobetasol Propionate ointment in US

New Delhi: Drug firm Lupin has launched generic Clobetasol Propionate ointment used for the treatment of inflammation and itching caused by a number of skin conditions in the US market.

The company has launched Clobetasol Propionate ointment USP in the strength of 0.05 per cent. It had earlier received approval for the product from theUnited States Food and Drug Administration (USFDA), Lupin said in a statement.

The company’s product is the generic version of Fougera Pharmaceuticals Inc’s Temovate ointment in the same strength, it added.

As per the IQVIA MAT June 2018 data, Clobetasol Propionate Ointment USP 0.05 per cent had annual sales of around USD 93.4 million in the US, it said.

“It is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses,” Lupin added.

Read Also: Lupin launches generic Potassium Chloride Oral Solution

The following two tabs change content below.
MD Team

MD Team

At Medical Dialogues, we are a team of young professionals strongly advocating of the transparency in the medical sector through the free flow of medical information, health and medical news. MD Team covers a variety of news related to the healthcare, pharma and medical device industry in India. Our team can be contacted at Contact no. 011-43720751

Source: Self
0 comment(s) on Lupin launches Clobetasol Propionate ointment in US

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted